Binosto (Alendronate Sodium) Patent Expiration, LOE Window & CMS Spending

Binosto (Alendronate Sodium) by Radius Health: FDA Orange Book LOE 2031-12-05, 6 AB generics, $478K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRadius Health
FDA Application & PathwayN202344 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-12-05
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$478K
2024 Medicare Part D Spend$459K
2024 Medicaid Spend$20K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel